Stine Nygaard Nielsen1, Kathrine Grell1,2, Jacob Nersting1, Thomas Leth Frandsen1, Lisa Lyngsie Hjalgrim1, Kjeld Schmiegelow3,4. 1. Department of Pediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, JMC-4072, Blegdamsvej 9, 2100, Copenhagen, Denmark. 2. Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark. 3. Department of Pediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, JMC-4072, Blegdamsvej 9, 2100, Copenhagen, Denmark. kjeld.schmiegelow@regionh.dk. 4. Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. kjeld.schmiegelow@regionh.dk.
Abstract
PURPOSE: Normal white blood cell counts (WBC) are unknown in children with acute lymphoblastic leukemia (ALL). Accordingly, 6-mercaptopurine (6MP) and methotrexate (MTX) maintenance therapy is adjusted by a common WBC target of 1.5-3.0 × 109/L. Consequently, the absolute degree of myelosuppression is unknown for the individual child and we wanted to evaluate this. METHODS: A median of 22 (range 8-27) 6MP/MTX metabolite samples and 100 (range 25-130) blood counts during therapy and 10 (range 2-15) off therapy were collected in 50 children with ALL. Differences between off-therapy and on-therapy WBCs [including absolute neutrophil (ANC) and lymphocyte counts (ALC)] were used to retrospectively approximate the absolute myelosuppression (="delta-") and association with age, sex and 6MP/MTX doses explored. We applied linear mixed models to estimate on-therapy counts by 6MP/MTX metabolites: DNA-incorporated thioguanine nucleotides (DNA-TGN), erythrocyte thioguanine nucleotides (ery-TGN), erythrocyte-methylated 6MP metabolites (ery-MeMP) and erythrocyte MTX polyglutamates with 2-6 glutamate residues (ery-MTXpg2-6). RESULTS: On-therapy WBC was correlated with ANC and ALC (r s = 0.84 and r s = 0.33, p values <0.001), whereas ANC was weakly correlated with ALC (r s = -0.11, p < 0.001), and neither significantly correlated with age. Off-therapy ALC, but not ANC, was strongly correlated with age (r s = -0.68 and -0.18, p < 0.001 and p = 0.22). Delta-ALC decreased with increasing age (r s = -0.69, p < 0.001). Incorporation of DNA-TGN was positively associated with ery-TGN (p < 0.001), ery-MeMP (p < 0.001) and ery-MTXpg2-6 (p = 0.047). On-therapy ALC decreased with increasing DNA-TGN level (p < 0.001, model adjusted for off-therapy ALC), whereas on-therapy ANC could not be modeled reliably. CONCLUSION: Measurements of 6MP/MTX metabolites could supplement blood counts in assessing therapy intensity, but require prospective validation.
PURPOSE: Normal white blood cell counts (WBC) are unknown in children with acute lymphoblastic leukemia (ALL). Accordingly, 6-mercaptopurine (6MP) and methotrexate (MTX) maintenance therapy is adjusted by a common WBC target of 1.5-3.0 × 109/L. Consequently, the absolute degree of myelosuppression is unknown for the individual child and we wanted to evaluate this. METHODS: A median of 22 (range 8-27) 6MP/MTX metabolite samples and 100 (range 25-130) blood counts during therapy and 10 (range 2-15) off therapy were collected in 50 children with ALL. Differences between off-therapy and on-therapy WBCs [including absolute neutrophil (ANC) and lymphocyte counts (ALC)] were used to retrospectively approximate the absolute myelosuppression (="delta-") and association with age, sex and 6MP/MTX doses explored. We applied linear mixed models to estimate on-therapy counts by 6MP/MTX metabolites: DNA-incorporated thioguanine nucleotides (DNA-TGN), erythrocyte thioguanine nucleotides (ery-TGN), erythrocyte-methylated 6MP metabolites (ery-MeMP) and erythrocyte MTX polyglutamates with 2-6 glutamate residues (ery-MTXpg2-6). RESULTS: On-therapy WBC was correlated with ANC and ALC (r s = 0.84 and r s = 0.33, p values <0.001), whereas ANC was weakly correlated with ALC (r s = -0.11, p < 0.001), and neither significantly correlated with age. Off-therapy ALC, but not ANC, was strongly correlated with age (r s = -0.68 and -0.18, p < 0.001 and p = 0.22). Delta-ALC decreased with increasing age (r s = -0.69, p < 0.001). Incorporation of DNA-TGN was positively associated with ery-TGN (p < 0.001), ery-MeMP (p < 0.001) and ery-MTXpg2-6 (p = 0.047). On-therapy ALC decreased with increasing DNA-TGN level (p < 0.001, model adjusted for off-therapy ALC), whereas on-therapy ANC could not be modeled reliably. CONCLUSION: Measurements of 6MP/MTX metabolites could supplement blood counts in assessing therapy intensity, but require prospective validation.
Authors: N Toft; H Birgens; J Abrahamsson; L Griškevičius; H Hallböök; M Heyman; T W Klausen; Ó G Jónsson; K Palk; K Pruunsild; P Quist-Paulsen; G Vaitkeviciene; K Vettenranta; A Åsberg; T L Frandsen; H V Marquart; H O Madsen; U Norén-Nyström; K Schmiegelow Journal: Leukemia Date: 2017-08-18 Impact factor: 11.528
Authors: Linea Natalie Toksvang; Bodil Als-Nielsen; Christopher Bacon; Ruta Bertasiute; Ximo Duarte; Gabriele Escherich; Elín Anna Helgadottir; Inga Rinvoll Johannsdottir; Ólafur G Jónsson; Piotr Kozlowski; Cecilia Langenskjöld; Kristi Lepik; Riitta Niinimäki; Ulrik Malthe Overgaard; Mari Punab; Riikka Räty; Heidi Segers; Inge van der Sluis; Owen Patrick Smith; Marion Strullu; Goda Vaitkevičienė; Hilde Skuterud Wik; Mats Heyman; Kjeld Schmiegelow Journal: BMC Cancer Date: 2022-05-02 Impact factor: 4.638
Authors: Nikki A Evensen; P Pallavi Madhusoodhan; Julia Meyer; Jason Saliba; Ashfiyah Chowdhury; David J Araten; Jacob Nersting; Teena Bhatla; Tiffaney L Vincent; David Teachey; Stephen P Hunger; Jun Yang; Kjeld Schmiegelow; William L Carroll Journal: Haematologica Date: 2018-02-15 Impact factor: 9.941
Authors: Rihwa Choi; Mi Ryung Chun; Jisook Park; Ji Won Lee; Hee Young Ju; Hee Won Cho; Ju Kyung Hyun; Hong Hoe Koo; Eun Sang Yi; Soo-Youn Lee Journal: Ann Lab Med Date: 2021-03-01 Impact factor: 3.464
Authors: Eun Sang Yi; Young Bae Choi; Rihwa Choi; Na Hee Lee; Ji Won Lee; Keon Hee Yoo; Ki Woong Sung; Soo-Youn Lee; Hong Hoe Koo Journal: Cancer Res Treat Date: 2017-09-13 Impact factor: 4.679